Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
170.60
-8.50 (-4.75%)
Jun 25, 2025, 10:37 AM - Market open
Ascendis Pharma Employees
Ascendis Pharma had 1,017 employees as of December 31, 2024. The number of employees increased by 138 or 15.70% compared to the previous year.
Employees
1,017
Change (1Y)
138
Growth (1Y)
15.70%
Revenue / Employee
$391,848
Profits / Employee
-$363,125
Market Cap
10.30B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,017 | 138 | 15.70% |
Dec 31, 2023 | 879 | 82 | 10.29% |
Dec 31, 2022 | 797 | 158 | 24.73% |
Dec 31, 2021 | 639 | 157 | 32.57% |
Dec 31, 2020 | 482 | 152 | 46.06% |
Dec 31, 2019 | 330 | 114 | 52.78% |
Dec 31, 2018 | 216 | 79 | 57.66% |
Dec 31, 2017 | 137 | 36 | 35.64% |
Dec 31, 2016 | 101 | 23 | 29.49% |
Dec 31, 2015 | 78 | 23 | 41.82% |
Dec 31, 2014 | 55 | 10 | 22.22% |
Dec 31, 2013 | 45 | 7 | 18.42% |
Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
ASND News
- 16 days ago - TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial - GlobeNewsWire
- 23 days ago - FDA Accepts TransCon® CNP NDA for Priority Review - GlobeNewsWire
- 5 weeks ago - Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction - Accesswire
- 6 weeks ago - New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide) - GlobeNewsWire
- 6 weeks ago - New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism - GlobeNewsWire
- 7 weeks ago - Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 - GlobeNewsWire
- 7 weeks ago - Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Ascendis Pharma Reports First Quarter 2025 Financial Results - GlobeNewsWire